Abstract
Reimmunization guidelines have recommended the inactivated HAV vaccine for hematopoietic stem cell transplant (HSCT) recipients living in or traveling to areas where hepatitis A is endemic. As a shift from high to medium hepatitis A endemicity has been observed in several countries in Latin America, we conducted a retrospective study to evaluate the prevalence of hepatitis A pre-bone marrow transplant (BMT) and the loss of specific antibodies in consecutive stored serum samples from 77 BMT recipients followed up from 82 to 1530 days. The prevalence of HAV antibodies was 92.2% before BMT. As vaccine was not available in Brazil when the samples were taken, it was assumed that this prevalence reflects natural infection. Survival analysis showed that the probability of becoming seronegative was 4.5% (±2.6%), 7.9% (±3.4%), 10.1% (±4.0%), 23.4% (±9.6%) at 1, 2, 3 and 4 years after transplant, respectively. The loss of HAV antibodies was significantly associated with longer follow-up (P=0.0015), younger age (P=0.049) and acute graft-versus-host disease (P=0.035). As most reimmunization protocols start around day +365, in developing countries with similar HAV endemicity, BMT recipients should have serological screening before HAV vaccination and the inactivated vaccine should be advised to those seronegative.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Debray D, Cullufi P, Devictor D, Fabre M, Bernard O . Liver failure in children with hepatitis A. Hepatology 1997; 26: 1018–1022.
Vitral CL, Yoshida CF, Lemos ER, Teixeira CS, Gaspar AM . Age-specific prevalence of antibodies to hepatitis A in children and adolescents from Rio de Janeiro, Brazil, 1978 and 1995. Relationship of prevalence to environmental factors. Mem Inst Oswaldo Cruz 1998; 93: 1–5.
Tanaka J . Hepatitis A shifting epidemiology in Latin America. Vaccine 2000; 18 (Suppl 1): S57–S60.
Ljungman P, Engelhard D, de la Camara R, Einsele H, Locasciulli A, Martino R et al. Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant 2005; 35: 737–746.
Dignani MC, Miceli MH, Rosa CM, Gatica J, Martínez-Rolón J, Pizzolato M . Loss of hepatitis A virus (HAV) antibodies after peripheral stem cell transplantation (PSCT). Bone Marrow Transplant 2003; 31: 809–812.
Glode MP, Evans GS, Fleming DW, Guerra FA, Le CT, Offit PA . Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999; 48: 1–37.
Gray RJ . A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141–1154.
Ljungman P, Duraj V, Magnius L . Response to immunization against polio after allogeneic marrow transplantation. Bone Marrow Transplant 1991; 7: 89–93.
Hammarstrom V, Pauksen K, Bjorkstrand B, Simonsson B, Oberg G, Ljungman P . Tetanus immunity in autologous bone marrow and blood stem cell transplant recipients. Bone Marrow Transplant 1998; 22: 67–71.
Parkkali T, Ruutu T, Stenvik M, Kuronen T, Kayhty H, Hovi T et al. Loss of protective immunity to polio, diphtheria and haemophilus influenzae type b after allogeneic bone marrow transplantation. APMIS 1996; 104: 383–388.
Machado CM, Gonçalves FB, Pannuti CS, Dulley FL, Souza VAUF . Measles in bone marrow transplant recipients during an outbreak in São Paulo, Brazil. Blood 2002; 99: 83–87.
Pauksen K, Linde A, Ljungman P, Bolme P, Lonnerholm G, Oberg G et al. Specific T and B cell immunity to measles after allogeneic and autologous bone marrow transplantation. Bone Marrow Transplant 1995; 16: 807–813.
Acknowledgements
We thank Drs FL Dulley, MCA Macedo, RL Silva and RS Saboya, from the BMT Program of University of São Paulo Medical School, for providing excellent patient care and without whose support this study would not have been possible.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Godoi, E., de Souza, V., Cakmak, S. et al. Loss of hepatitis A virus antibodies after bone marrow transplantation. Bone Marrow Transplant 38, 37–40 (2006). https://doi.org/10.1038/sj.bmt.1705391
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705391
Keywords
This article is cited by
-
Hospitalizations for vaccine-preventable infections among pediatric hematopoietic cell transplantation recipients in the first 5 years after transplantation
Bone Marrow Transplantation (2021)
-
Significant loss of hepatitis A Ab after allogeneic hematopoietic SCT in pediatric patients
Bone Marrow Transplantation (2010)